ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
Dow Jones
42.840,26
1,18%
Euro vs US Dollar
1,043
0,00%
Bitcoin
97.079,55
-0,13%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Sangamo Therapeutics Inc (SGMO) Börsenkurse

Sangamo Therapeutics Inc

Sangamo Therapeutics Inc (SGMO)

NASDAQ
2,47
0,16
(6,93%)
Geschlossen 22 Dezember 10:00PM
Verzögert um 15 Minuten
2,48
0,01
(0,40%)
Nach Börsenschluss: 1:54AM
Verzögert um 15 Minuten

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
2,48
Gebot
2,06
Fragen
3,50
Volumen
13.730.334
2,2501 Tagesbereich 2,53
0,304 52-Wochen-Bereich 3,179
Marktkapitalisierung
517,444M
Handelsende
2,31
Handelsbeginn
2,34
Letzte Trade
33
@
2.49
Letzter Handelszeitpunkt
Finanzvolumen
US$ 33.506.112
VWAP
2,4403
Durchschnittliches Volumen (3 Mio.)
8.419.296
Ausgegebene Aktien
208.646.870
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-2,01
Gewinn pro Aktie (EPS)
-1,24
Erlöse
176,23M
Nettogewinn
-257,83M

Über Sangamo Therapeutics Inc

Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemoph... Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies. Mehr anzeigen

Sektor
Biological Pds,ex Diagnstics
Branche
Biological Pds,ex Diagnstics
Website
www.sangamo.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Sangamo Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker SGMO. The last closing price for Sangamo Therapeutics was US$2,31. Over the last year, Sangamo Therapeutics shares have traded in a share price range of US$ 0,304 to US$ 3,179.

Sangamo Therapeutics currently has 208.646.870 shares in issue. The market capitalisation of Sangamo Therapeutics is US$481,97 million. Sangamo Therapeutics has a price to earnings ratio (PE ratio) of -2.01.

SGMO Neueste Nachrichten

Weitere Nachrichten

Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

- Agreement grants Astellas rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - Sangamo to receive a $20 million upfront license...

19 Dezember 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

26 November 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

26 November 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

26 November 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

26 November 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

26 November 2024
Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness

20 November 2024
Edgar (US Regulatory)

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

Sangamo plans to initiate enrollment of patients in the Phase 1/2 study for ST-503 in mid-2025 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S...

19 November 2024
Business Wire

Form S-8 - Securities to be offered to employees in employee benefit plans

12 November 2024
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.43521.2713936432.0452.841.99128804732.44403813CS
40.559929.15993958651.92012.841.7968502622.2440226CS
121.62188.3720930230.863.1790.743684192961.89607521CS
262.0549483.3921430250.42513.1790.304109989401.15823741CS
522.085200.43.1790.30466122101.08844956CS
156-5.3249-68.22508936697.80498.650.291133529671.7159525CS
260-6.18-71.36258660518.6619.430.291126696473.90153916CS

SGMO - Frequently Asked Questions (FAQ)

What is the current Sangamo Therapeutics share price?
The current share price of Sangamo Therapeutics is US$ 2,48
How many Sangamo Therapeutics shares are in issue?
Sangamo Therapeutics has 208.646.870 shares in issue
What is the market cap of Sangamo Therapeutics?
The market capitalisation of Sangamo Therapeutics is USD 481,97M
What is the 1 year trading range for Sangamo Therapeutics share price?
Sangamo Therapeutics has traded in the range of US$ 0,304 to US$ 3,179 during the past year
What is the PE ratio of Sangamo Therapeutics?
The price to earnings ratio of Sangamo Therapeutics is -2,01
What is the cash to sales ratio of Sangamo Therapeutics?
The cash to sales ratio of Sangamo Therapeutics is 2,94
What is the reporting currency for Sangamo Therapeutics?
Sangamo Therapeutics reports financial results in USD
What is the latest annual turnover for Sangamo Therapeutics?
The latest annual turnover of Sangamo Therapeutics is USD 176,23M
What is the latest annual profit for Sangamo Therapeutics?
The latest annual profit of Sangamo Therapeutics is USD -257,83M
What is the registered address of Sangamo Therapeutics?
The registered address for Sangamo Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Sangamo Therapeutics website address?
The website address for Sangamo Therapeutics is www.sangamo.com
Which industry sector does Sangamo Therapeutics operate in?
Sangamo Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
MYSZMy Size Inc
US$ 4,2001
(211,12%)
121,03M
NVNINVNI Group Ltd
US$ 8,26
(209,36%)
78,06M
TPICTPI Composites Inc
US$ 2,45
(100,82%)
34M
ICGIntchains Group Ltd
US$ 8,77
(88,60%)
527,94k
HSDTHelius Medical Technologies Inc
US$ 0,884851
(84,34%)
121,95M
CYNCYNGN Inc
US$ 0,4603
(-71,41%)
27,91M
MTEMMolecular Templates Inc
US$ 0,1502
(-57,09%)
8,75M
PRFXPainReform Ltd
US$ 5,15
(-53,85%)
2,94M
GALTGalectin Therapeutics Inc
US$ 1,03
(-48,50%)
9,27M
BCABBioAtla Inc
US$ 0,6923
(-41,82%)
6,25M
EDBLEdible Garden AG Inc
US$ 0,24
(65,06%)
354,32M
APTOAptose Biosciences Inc
US$ 0,28
(64,51%)
305,1M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,606999
(6,49%)
292,16M
NVDANVIDIA Corporation
US$ 134,70
(3,08%)
287,21M
PLTRPalantir Technologies Inc
US$ 80,55
(8,54%)
277,63M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
SGMO
Sangamo Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten